Real-World Data Partnership On COVID-19: US FDA Drawn To Consistency, Diversity of Aetion's Datasets

FDA's Amy Abernethy tells the Pink Sheet that initial priorities are likely to include studying COVID-19 natural history and how patients are faring under various medication regimens. Aetion's ability to perform consistent analyses across a variety of data sets was key for FDA in selecting the the partnership, which grew from Reagan-Udall Foundation and Friends of Cancer Research's Evidence Accelerator project.

The real world signpost with blue sky and clouds
FDA is embarking on a new real-world data partnership with Aetion to advance its understanding of COVID-19 • Source: Shutterstock

The US Food and Drug Administration announced a new COVID-19 real-world data partnership with Aetion this week, a collaboration that was attractive to the regulatory agency because of Aetion’s ability to provide consistent analysis across multiple different data sets, Principal Deputy Commissioner and Acting Chief Information Officer Amy Abernethy told the Pink Sheet.

The Aetion platform provides “a mechanism for consistent analysis of different real-world data sets so that then we can then...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Real-World Evidence

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

EMA Advances Use Of Real-World Data By HTAs And Payers

 
• By 

Results from the first pilot real-world evidence study commissioned by the European Medicines Agency to help HTA bodies and payers characterize patients with multiple myeloma have drawn positive feedback.

EU Ocaliva Withdrawal Recommendation Based On ‘Flawed’ Studies

 

Overreliance on “problematic” trials while overlooking the value of real-world evidence could affect the development of other rare disease treatments, according to Advanz’s CEO.

More from Clinical Trials

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

US FDA’s MIDD Program Could Expand Beyond Quarterly Requests, But Needs Resources

 

An FDA official said the agency is considering allowing MIDD meeting requests to be submitted more often, but must have a plan to deal with the likely increased demand.